

Freedom of Information Request	FOI 21-453	1 st November 2021
--------------------------------	------------	-------------------------------

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the systemic anti-cancer therapies listed below?

- Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) as a single agent
- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
- Atezolizumab + Nab-paclitaxel/Paclitaxel
- Capecitabine as a single agent
- Carboplatin or Cisplatin as a single agent
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fluorouracil
- Fulvestrant as a single agent
- Goserelin
- Lapatinib
- Neratinib
- Olaparib
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Pertuzumab + Trastuzumab + Docetaxel
- Platinum (e.g. carboplatin or cisplatin) as a single agent
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Talazoparib
- Tamoxifen
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab as a single agent
- Trastuzumab emtansine
- Trastuzumab deruxtecan
- Any other active systemic anti-cancer therapy

Q2. In the past 3 months, how many early/locally advanced (Stages I to IIIC) breast cancer patients were treated with an Aromatase Inhibitor (anastrozole, exemestane, Letrozole) as a single agent?

All Systematic Anti Cancer Therapies for breast cancer are delivered by Velindre NHS Trust.

A Freedom of Information request can be submitted to Velindre NHS Trust using the following link:

<https://velindre.nhs.wales/about-us/publications/freedom-of-information/>